Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

BACKGROUND. Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those wi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Leichman, Lawrence, Groshen, Susan, O’Neil, Bert H., Messersmith, Wells, Berlin, Jordan, Chan, Emily, Leichman, Cynthia G., Cohen, Steven J., Cohen, Deirdre, Lenz, Heinz-Josef, Gold, Philip, Boman, Bruce, Fielding, Anitra, Locker, Gershon, Cason, Ronald C., Hamilton, Stan R., Hochster, Howard S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2016
Konular:
Gastrointestinal Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746089/
https://ncbi.nlm.nih.gov/pubmed/26786262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller